These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1649863)

  • 21. Treatment of obesity-associated hypertension.
    Dustan HP; Weinsier RL
    Ann Epidemiol; 1991 May; 1(4):371-9. PubMed ID: 1669518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.
    Amador N; Encarnación JJ; Guízar JM; Rodríguez L; López M
    J Hum Hypertens; 2005 Apr; 19(4):277-83. PubMed ID: 15674406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of a Modest Weight Loss in Normalizing Blood Pressure in Obese Subjects on Antihypertensive Drugs.
    Gilardini L; Redaelli G; Croci M; Conti A; Pasqualinotto L; Invitti C
    Obes Facts; 2016; 9(4):251-8. PubMed ID: 27454447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: therapeutic implications.
    Zusman RM; Christensen DM; Higgins J; Boucher CA
    J Cardiovasc Pharmacol; 1992 Aug; 20(2):216-22. PubMed ID: 1381012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
    Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects on Cardiovascular Risk Scores and Vascular Age After Aerobic Exercise and Nutritional Intervention in Sedentary and Overweight/Obese Adults with Primary Hypertension: The EXERDIET-HTA Randomized Trial Study.
    Gorostegi-Anduaga I; Maldonado-Martín S; MartinezAguirre-Betolaza A; Corres P; Romaratezabala E; Whittaker AC; Francisco-Terreros S; Pérez-Asenjo J
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):361-368. PubMed ID: 30251109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients.
    MacMahon SW; Wilcken DE; Macdonald GJ
    N Engl J Med; 1986 Feb; 314(6):334-9. PubMed ID: 2935737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of dietary change on the return of hypertension after withdrawal of prolonged antihypertensive therapy (DISH). Dietary Intervention Study of Hypertension.
    Blaufox MD; Langford HG; Oberman A; Hawkins CM; Wassertheil-Smoller SW; Cutter GR
    J Hypertens Suppl; 1984 Dec; 2(3):S179-81. PubMed ID: 6599665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects.
    Reid CM; Dart AM; Dewar EM; Jennings GL
    J Hypertens; 1994 Mar; 12(3):291-301. PubMed ID: 8021483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.
    Kuperstein R; Sasson Z
    Circulation; 2000 Oct; 102(15):1802-6. PubMed ID: 11023935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
    Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
    Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
    Gerdts E; Papademetriou V; Palmieri V; Boman K; Björnstad H; Wachtell K; Giles TD; Dahlöf B; Devereux RB;
    Am J Cardiol; 2002 Feb; 89(4):399-402. PubMed ID: 11835919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac determinants of regression of left ventricular hypertrophy in essential hypertension with antihypertensive treatment.
    Sugishita Y; Iida K; Yukisada K; Ito I
    J Am Coll Cardiol; 1990 Mar; 15(3):665-71. PubMed ID: 2137479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension.
    Petersen JR; Drabaek H; Gleerup G; Mehlsen J; Petersen LJ; Winther K
    Angiology; 1996 Mar; 47(3):233-40. PubMed ID: 8638865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents.
    Gottdiener JS; Reda DJ; Williams DW; Materson BJ; Cushman W; Anderson RJ
    Circulation; 1998 Jul; 98(2):140-8. PubMed ID: 9679720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
    Greve AM; Olsen MH; Bella JN; Lønnebakken MT; Gerdts E; Okin PM; Palmieri V; Boman K; Nieminen MS; Omvik P; Dahlöf B; Devereux RB; Wachtell K
    Am J Hypertens; 2012 Sep; 25(9):1017-23. PubMed ID: 22695506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.